Now in its 4th year, the digital AFDD summit is the industry’s definitive guide to turning mechanistic understanding of fibrosis into clinically effective therapeutics across disease areas. With 3 days of in-depth cutting-edge case studies and the highest calibre of discussions from cross-disciplinary fibrosis heavy-weights, AFDD will bridge the current translational gap to anti-fibrotic drug development success
Join 100+ fibrosis experts at this fully digital event to build a comprehensive network with like-minded peers and hurdle your translational drug development challenges to accelerate the development of more clinically effective drugs.
Conference Only: USD 2099.0,
Full Access: USD 2948.0
Speakers: Andrew Billin Senior Director, Biomarker Sciences Gilead, Bob Willette Senior Fibrosis Advisor ImmunoMet, Cory Hogaboam Professor of Medicine and Adjunct Professor of Pathology Cedars Sinai Medical Centre, Eric White Director Clinical Development and Medical Affairs – IPF/ILD Boehringer Ingelheim, James Trevaskis Director, Fibrosis Biology, Research Gilead, Jamie Bates Director, Fibrosis Gilead, Jeremy Duffield Vice President Vertex Pharmaceuticals, Johnathan Epstein William Wikoff Smith Professor, Executive Vice Dean and Chief Scientific Officer Perelman School of Medicine at the University of Pennsylvania, Karim Christian El Kasmi Laboratory Head Immunology and Respiratory Macrophage Biology Innate Immunity Boehringer Ingelheim, Ke Cheng Co-founder BreStem Therapeutics, Kevin Fowler Principal The Voice of the Patient, Rana Herro Assistant Professor Cincinnati Children’s Hospital, Rob Slack Director of Pharmacology Galecto, Rugmani Iyer Senior Scientist II Merck, Samir Ounzain Chief Executive Officer and Scientific Co-Founder HAYA Therapeutics, Scott MacDonnell Associate Director Cardiovascular, Fibrosis, and Renal Research Regeneron Pharmaceuticals, Sunhwa Kim Principal Scientist Merck, Wim van Schooten Chief Scientific Officer TeneoBio
Time: 8:30 am - 6:00 pm